Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,987 | 260 | 1,691 |
| Samples | 1,707 | 230 | 1,444 |
| Peptides | 1,243 | 165 | 1,107 |
Function
PREX2 · Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2
The protein encoded by this gene belongs to the phosphatidylinositol 3,4,5-trisphosphate (PIP3)-dependent Rac exchanger (PREX) family, which are Dbl-type guanine-nucleotide exchange factors for Rac family small G proteins. Structural domains of this protein include the catalytic diffuse B-cell lymphoma homology and pleckstrin homology (DHPH) domain, two disheveled, EGL-10, and pleckstrin homology (DEP) domains, two PDZ domains, and a C-terminal inositol polyphosphate-4 phosphatase (IP4P) domain that is found in one of the isoforms. This protein facilitates the exchange of GDP for GTP on Rac1, allowing the GTP-bound Rac1 to activate downstream effectors. Studies also show that the pleckstrin homology domain of this protein interacts with the phosphatase and tensin homolog (PTEN) gene product to inhibit PTEN phosphatase activity, thus activating the phosphoinositide-3 kinase (PI3K) signaling pathway. Conversely, the PTEN gene product has also been shown to inhibit the GEF activity of this protein. This gene plays a role in insulin-signaling pathways, and either mutations or overexpression of this gene have been observed in some cancers. [provided by RefSeq, Apr 2016].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000288368 | Q70Z35 | 1,987 | 1,243 |
Gene Properties
Recurrent Mutations
All 1243 amino-acid changes on canonical ENST00000288368 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PREX2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PREX2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 4/26 15% | 0/0 0% |
| Melanoma | 22/210 10% | 283/1899 15% |
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Gastric Carcinoma | 6/74 8% | 138/1809 8% |
| Squamous Cell Lung Carcinoma | 8/57 14% | 54/810 7% |
| Esophageal Carcinoma | 5/23 22% | 46/769 6% |
| Endometrial Carcinoma | 8/42 19% | 34/612 6% |
| Colorectal Carcinoma | 28/143 20% | 181/3239 6% |
| Non-Small Cell Lung Carcinoma | 35/304 12% | 60/1390 4% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 42/752 6% |
| Chordoma | 0/7 0% | 1/13 8% |
| Other Solid Cancers | 1/94 1% | 78/1515 5% |
| Osteosarcoma | 5/45 11% | 4/166 2% |
| Neuroendocrine Tumour | 15/154 10% | 15/577 3% |
| Bladder Carcinoma | 1/58 2% | 39/956 4% |
| Rhabdomyosarcoma | 0/33 0% | 8/171 5% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Hepatocellular Carcinoma | 5/46 11% | 79/2210 4% |
| Other Sarcomas | 7/69 10% | 18/699 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Ewings Sarcoma | 5/63 8% | 4/262 2% |
| Mesothelioma | 4/62 6% | 2/165 1% |
| Unknown | 1/10 10% | 0/29 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 64/2550 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Burkitts Lymphoma | 5/32 16% | 0/196 0% |
| Cervical Carcinoma | 2/35 6% | 8/422 2% |
| Breast Carcinoma | 4/144 3% | 70/3264 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
Mutation Distribution
Where PREX2 is mutated · all tissues, split by cell line vs tissue
How many mutations in PREX2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,987 mutations in PREX2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|